Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc)

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan

Tseng, Yu-Tzu
Yang, Chia-Jui
Chang, Sui-Yuan
Lin, Shu-Wen
Tsai, Mao-Song
Liu, Wen-Chun
Wu, Pei-Ying
Su, Yi-Ching
Luo, Yu-Zhen
Yang, Shang-Ping
Hung, Chien-Ching
Chang, Shan-Chwen

December 2014

SummaryObjectivesTo retrospectively investigate the incidence of and factors associated with skin ra...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Strategies for Management of Anti-Retroviral Therapy/INSIGHT
DAD Study Groups

January 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

Lundgren, J D
Neuhaus, J
Babiker, A
Cooper, D
Duprez, D
El-Sadr, W
Emery, S
Gordin, F
Kowalska, J
Phillips, A
Prineas, R J
Sabin, C A
Tracy, R
Weber, R
Grund, B
Neaton, J D

September 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL)

Floridia M
Bucciardini R
Fragola V
Galluzzo CM
Giannini G
Pirillo MF
Amici R
Andreotti M
Ricciardulli D
Tomino C
Vella S
ISS IP1 study group
Abrescia N
Boccia L
Butrico E
Vegezio A
Busto A
Aceti A
Mura MS
Calia GN
Lovigu C
Babudieri S
Oggiano S
Masia R
Aiuti F
Mezzaroma I
D'Offizi G
Carlesimo M
Giovannetti A
Pinter E
Alberici F
Sisti M
Sacchini D
Faggi A
Paolillo F
Angioni G
Meloni G
Angioni S
Albeltino G
Porcu F
Bassetti D
Gatti G
Di Biagio A
Mazzarello G
Bonazzi L
Barchi E
Testa L
Ursitti MA
Zoboli G
Cadeo GP
Barni C
Bertelli D
Cadrobbi P
Cattelan A
Meneghetti F
Sattin A
Scaggiante R
Giacomazzi D
Caggese L
Moioli MC
Volonterio A
Schlacht I
Errante I
Irato L
Caputo R
Cusini M
Cagnel A
Valsecchi L
Beretta R
Carosi G
Chiodera A
Castelli F
Tomasoni L
Cattane AA
Nasta P
Chiodo F
Colangeli V
Manfredi R
Borderi M
Donzelli C
Guerra E
Chirianni A
Gargiulo M
Montesarchio V
Punzi R
Sangiovanni V
Gnarini R
Ciammarughi R
Arlotti M
Martelli ML
Romagnoli G
Boschi A
Colomba A
Prestileo T
Fundaró S
Di Lorenzo F
Mineo M
Dalle Nogare ER
Di Perri G.
CONCIA, Ercole

January 2004

BACKGROUND: Most of the studies evaluating rash in HIV-positive patients have focused on nonnucleos...

Lin, Kuan-Yin
陳茂源

June 2017

Objectives: The study aimed to investigate the incidence of and associated factors with skin rashes ...

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.

Pei-Ying Wu
Chien-Yu Cheng
Chun-Eng Liu
Yi-Chien Lee
Chia-Jui Yang
Mao-Song Tsai
Shu-Hsing Cheng
Shih-Ping Lin
De-Yu Lin
Ning-Chi Wang
Yi-Chieh Lee
Hsin-Yun Sun
Hung-Jen Tang
Chien-Ching Hung

January 2017

OBJECTIVES:Two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain...

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?

Fred Stephen Sarfo (139071)
Maame Anima Sarfo (550970)
Betty Norman (550971)
Richard Phillips (205457)
David Chadwick (300132)

April 2014

<div><p>Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequen...

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan

Wu Pei-Ying
Cheng Chien-Yu
Liu Chun-Eng
Lee Yi-Chien
Yang Chia-Jui
Tsai Mao-Song
Cheng Shu-Hsing
Lin Shih-Ping
Lin De-Yu
Wang Ning-Chi
Lee Yi-Chieh
Sun Hsin-Yun
Tang Hung-Jen
Hung Chien-Ching

February 2017

)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain the preferred or altern...

Incidence and Risk Factors for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)-Related Rash in Thai Children with HIV Infection

Sunitha Vemula Md
Stephen Kerr Md
Chitsanu Pancharoen Md
Arida Siripong Md
Pope Kosalaraksa Md
Chulapan Engchanil Md
Arpa Chuamchaitrakool Md
Jintana Intasan Md
Pagakrong Lumbiganond Md
Praphan Phanuphak Md
Jintanat Ananworanich Md

February 2015

The present study evaluated the incidence and risk factors that correlated with the development of n...

Incidence and Determinants of Nevirapine and Efavirenz- Related Skin Rashes in West Africans: Nevirapine’s Epitaph?

Fred Stephen Sarfo
Maame Anima Sarfo
Betty Norman
Richard Phillips
David Chadwick

January 2013

Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequently lead...

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

Fred Stephen Sarfo
Maame Anima Sarfo
Betty Norman
Richard Phillips
David Chadwick

Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequently lead...

Selecting patients who can be re-challenged with Nevirapine in case of skin rash with Efavirenz – A Study

N. Dutta
D. Modak
R. De
S. Pain
S. K. Guha

May 2017

Introduction and Objectives: A common adverse effect of Efavirenz (EFV) – a first line drug used in ...

Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study

P. Bonfanti
L. Valsecchi
F. Parazzini
S. Carradori
L. Pusterla
P. Fortuna
L. Timillero
F. Alessi
G. Ghiselli
A. Gabbuti
E. Di Cintio
C. Martinelli
I. Faggion
S. Landonio
T. Quirino
Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group

March 2000

Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued beca...

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy

Zhang, S.
Sighem, A. van
Kesselring, A.
Gras, L.
Prins, J.M.
Hassink, E.
Kauffmann, R.
Richter, C.
Wolf, F. de
Reiss, P.
Koopmans †, P.P.
Keuter, M.
Ven, A.J.A.M. van der
Hofstede, H.J.M. ter
Dofferhoff, A.S.M.
Warris, A.
Crevel, R. van
et al.

January 2015

OBJECTIVES: Certain non-AIDS-related diseases have been associated with immunodeficiency and HIV RNA...

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan

Tseng, Yu-Tzu
張上淳

June 2017

Objectives: To retrospectively investigate the incidence of and factors associated with skin rashes ...

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan

Tseng, Yu-Tzu
Yang, Chia-Jui
Chang, Sui-Yuan
Lin, Shu-Wen
Tsai, Mao-Song
Liu, Wen-Chun
Wu, Pei-Ying
Su, Yi-Ching
Luo, Yu-Zhen
Yang, Shang-Ping
Hung, Chien-Ching
Chang, Shan-Chwen

December 2014

SummaryObjectivesTo retrospectively investigate the incidence of and factors associated with skin ra...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Strategies for Management of Anti-Retroviral Therapy/INSIGHT
DAD Study Groups

January 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

Lundgren, J D
Neuhaus, J
Babiker, A
Cooper, D
Duprez, D
El-Sadr, W
Emery, S
Gordin, F
Kowalska, J
Phillips, A
Prineas, R J
Sabin, C A
Tracy, R
Weber, R
Grund, B
Neaton, J D

September 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL)

Floridia M
Bucciardini R
Fragola V
Galluzzo CM
Giannini G
Pirillo MF
Amici R
Andreotti M
Ricciardulli D
Tomino C
Vella S
ISS IP1 study group
Abrescia N
Boccia L
Butrico E
Vegezio A
Busto A
Aceti A
Mura MS
Calia GN
Lovigu C
Babudieri S
Oggiano S
Masia R
Aiuti F
Mezzaroma I
D'Offizi G
Carlesimo M
Giovannetti A
Pinter E
Alberici F
Sisti M
Sacchini D
Faggi A
Paolillo F
Angioni G
Meloni G
Angioni S
Albeltino G
Porcu F
Bassetti D
Gatti G
Di Biagio A
Mazzarello G
Bonazzi L
Barchi E
Testa L
Ursitti MA
Zoboli G
Cadeo GP
Barni C
Bertelli D
Cadrobbi P
Cattelan A
Meneghetti F
Sattin A
Scaggiante R
Giacomazzi D
Caggese L
Moioli MC
Volonterio A
Schlacht I
Errante I
Irato L
Caputo R
Cusini M
Cagnel A
Valsecchi L
Beretta R
Carosi G
Chiodera A
Castelli F
Tomasoni L
Cattane AA
Nasta P
Chiodo F
Colangeli V
Manfredi R
Borderi M
Donzelli C
Guerra E
Chirianni A
Gargiulo M
Montesarchio V
Punzi R
Sangiovanni V
Gnarini R
Ciammarughi R
Arlotti M
Martelli ML
Romagnoli G
Boschi A
Colomba A
Prestileo T
Fundaró S
Di Lorenzo F
Mineo M
Dalle Nogare ER
Di Perri G.
CONCIA, Ercole

January 2004

BACKGROUND: Most of the studies evaluating rash in HIV-positive patients have focused on nonnucleos...

Lin, Kuan-Yin
陳茂源

June 2017

Objectives: The study aimed to investigate the incidence of and associated factors with skin rashes ...

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.

Pei-Ying Wu
Chien-Yu Cheng
Chun-Eng Liu
Yi-Chien Lee
Chia-Jui Yang
Mao-Song Tsai
Shu-Hsing Cheng
Shih-Ping Lin
De-Yu Lin
Ning-Chi Wang
Yi-Chieh Lee
Hsin-Yun Sun
Hung-Jen Tang
Chien-Ching Hung

January 2017

OBJECTIVES:Two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain...

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?

Fred Stephen Sarfo (139071)
Maame Anima Sarfo (550970)
Betty Norman (550971)
Richard Phillips (205457)
David Chadwick (300132)

April 2014

<div><p>Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequen...

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan

Wu Pei-Ying
Cheng Chien-Yu
Liu Chun-Eng
Lee Yi-Chien
Yang Chia-Jui
Tsai Mao-Song
Cheng Shu-Hsing
Lin Shih-Ping
Lin De-Yu
Wang Ning-Chi
Lee Yi-Chieh
Sun Hsin-Yun
Tang Hung-Jen
Hung Chien-Ching

February 2017

)ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain the preferred or altern...

Incidence and Risk Factors for Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)-Related Rash in Thai Children with HIV Infection

Sunitha Vemula Md
Stephen Kerr Md
Chitsanu Pancharoen Md
Arida Siripong Md
Pope Kosalaraksa Md
Chulapan Engchanil Md
Arpa Chuamchaitrakool Md
Jintana Intasan Md
Pagakrong Lumbiganond Md
Praphan Phanuphak Md
Jintanat Ananworanich Md

February 2015

The present study evaluated the incidence and risk factors that correlated with the development of n...

Incidence and Determinants of Nevirapine and Efavirenz- Related Skin Rashes in West Africans: Nevirapine’s Epitaph?

Fred Stephen Sarfo
Maame Anima Sarfo
Betty Norman
Richard Phillips
David Chadwick

January 2013

Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequently lead...

Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?

Fred Stephen Sarfo
Maame Anima Sarfo
Betty Norman
Richard Phillips
David Chadwick

Non-nucleoside reverse transcriptase inhibitor (NNRTI) associated rash is common and frequently lead...

Selecting patients who can be re-challenged with Nevirapine in case of skin rash with Efavirenz – A Study

N. Dutta
D. Modak
R. De
S. Pain
S. K. Guha

May 2017

Introduction and Objectives: A common adverse effect of Efavirenz (EFV) – a first line drug used in ...

Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study

P. Bonfanti
L. Valsecchi
F. Parazzini
S. Carradori
L. Pusterla
P. Fortuna
L. Timillero
F. Alessi
G. Ghiselli
A. Gabbuti
E. Di Cintio
C. Martinelli
I. Faggion
S. Landonio
T. Quirino
Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group

March 2000

Objective: To assess the probability that protease inhibitor (PI) therapy might be discontinued beca...

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy

Zhang, S.
Sighem, A. van
Kesselring, A.
Gras, L.
Prins, J.M.
Hassink, E.
Kauffmann, R.
Richter, C.
Wolf, F. de
Reiss, P.
Koopmans †, P.P.
Keuter, M.
Ven, A.J.A.M. van der
Hofstede, H.J.M. ter
Dofferhoff, A.S.M.
Warris, A.
Crevel, R. van
et al.

January 2015

OBJECTIVES: Certain non-AIDS-related diseases have been associated with immunodeficiency and HIV RNA...

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan

Tseng, Yu-Tzu
張上淳

June 2017

Objectives: To retrospectively investigate the incidence of and factors associated with skin rashes ...

Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan

Tseng, Yu-Tzu
Yang, Chia-Jui
Chang, Sui-Yuan
Lin, Shu-Wen
Tsai, Mao-Song
Liu, Wen-Chun
Wu, Pei-Ying
Su, Yi-Ching
Luo, Yu-Zhen
Yang, Shang-Ping
Hung, Chien-Ching
Chang, Shan-Chwen

December 2014

SummaryObjectivesTo retrospectively investigate the incidence of and factors associated with skin ra...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

Strategies for Management of Anti-Retroviral Therapy/INSIGHT
DAD Study Groups

January 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

Lundgren, J D
Neuhaus, J
Babiker, A
Cooper, D
Duprez, D
El-Sadr, W
Emery, S
Gordin, F
Kowalska, J
Phillips, A
Prineas, R J
Sabin, C A
Tracy, R
Weber, R
Grund, B
Neaton, J D

September 2008

BACKGROUND: Two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)--abacavir and didanosine--may...

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc)

Abstract

Extracted data

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc)

Abstract

Extracted data

Related items

Related items

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (&lt;50 cells/mmc)

Abstract

Extracted data

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (&lt;50 cells/mmc)

Abstract

Extracted data

Related items

Related items

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc)

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc)